Nearmap Ltd
F:QSX1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Nearmap Ltd
F:QSX1
|
AU |
|
Definium Therapeutics Inc
NASDAQ:DFTX
|
US |
|
P
|
Powerhouse Energy Group PLC
LSE:PHE
|
UK |
|
E
|
Europris ASA
XMUN:2RG
|
NO |
|
Cellectis SA
F:ZVA
|
FR |
|
E
|
Europris ASA
DUS:2RG
|
NO |
|
O
|
Obayashi Corp
DUS:OBA
|
JP |
|
S
|
Sunnova Energy International Inc
XBER:7SE
|
US |
|
C
|
Cannabist Company Holdings Inc
NEO:CBST
|
US |
|
B
|
Bravura Solutions Ltd
SWB:BRA
|
AU |
|
Kodiak Gas Services Inc
F:Q41
|
US |
|
B
|
British Land Company PLC
F:BLD
|
UK |
|
A
|
Alphageo (India) Ltd
BSE:526397
|
IN |
|
Innate Pharma SA
PAR:IPH
|
FR |
|
C
|
Cogeco Communications Inc
XBER:COG
|
CA |
|
Calnex Solutions PLC
F:CSO
|
UK |
|
T
|
Tribe Property Technologies Inc
OTC:TRPTF
|
CA |
|
T
|
Tribe Property Technologies Inc
F:7HZ
|
CA |
|
BioRestorative Therapies Inc
F:9OF
|
US |
|
Mighty Kingdom Ltd
ASX:FTI
|
AU |
|
M
|
Mkango Resources Ltd
F:ZMK
|
CA |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is QSX1's stock price target?
Not Available
QSX1 does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Nearmap Ltd?
Projected CAGR
22%
Over the last 8 years, the compound annual growth rate for Revenue has been 28%. The projected CAGR for the next 3 years is 22%.